
浏览全部资源
扫码关注微信
1. 重庆三峡中心医院肿瘤科
2. 重庆三峡中心医院超声科
3. 重庆三峡中心医院中医科
4. 重庆三峡中心医院儿童分院
纸质出版日期:2010,
扫 描 看 全 文
[1]冉文华,黄朝森,王恩元,任必男,黄小平,莫运波,张军.局限期小细胞肺癌中药维持治疗临床观察[J].重庆医科大学学报,2010,35(11):1756-1758.
RAN Wen-hua, et al. Clinical reasearch of limited stage small cell lung cancer treated by Chinese medcine after chemoradiotherapy[J]. Journal of Chongqing Medical University, 2010,35(11):1756-1758.
[1]冉文华,黄朝森,王恩元,任必男,黄小平,莫运波,张军.局限期小细胞肺癌中药维持治疗临床观察[J].重庆医科大学学报,2010,35(11):1756-1758. DOI: 10.13406/j.cnki.cyxb.2010.11.042.
RAN Wen-hua, et al. Clinical reasearch of limited stage small cell lung cancer treated by Chinese medcine after chemoradiotherapy[J]. Journal of Chongqing Medical University, 2010,35(11):1756-1758. DOI: 10.13406/j.cnki.cyxb.2010.11.042.
目的:探讨常规化放疗后用中药维持治疗局限期小细胞肺癌能否提高生存率。方法:70例未经手术治疗的局限期小细胞肺癌病例随机分为化放疗组(对照组)和化放疗后中药维持治疗组(研究组)
每组分别为35例。对照组与研究组的化放疗方案均相同
研究组于化放疗治疗结束后加服喜丹汤治疗
分强化阶段、巩固阶段、维持阶段中药治疗。结果:对照组与研究组1、2、3、5年生存率分别为74.3%、31.4%、14.3%、11.4%和77.1%、40.0%、28.6%、22.9%
中位生存期分别为16.1个月、22.3个月
2、3、5年生存率比较差异有统计学意义(P<0.05)。研究组、对照组强化阶段同期比较发生胃肠道反应及Ⅰ、Ⅱ级骨髓抑制均无明显统计学差异(P>0.05)。结论:常规化放疗后加用中药维持治疗能提高局限期小细胞肺癌患者的生存率
延长其生存期
不增加毒副反应。
Objective:To investigate whether Chinese traditional medcine improve survival rate of limited stage small cell lung cancer(LS-SCLC) patients after conventional chemoradiotherapy.Method: Seventy patients with LS-SCLC treated without surgery were randomized into two groups.The control group 35 examples treated by chemoradiotherapy
35 cases of patients in the research group treated based on chemoradiotherapy plus Chinese Medicine
XIDAN soup was given by mouth during strengthen phase
consolidation phase and maintenance phase.Result:The overall 1-
2-
3-
5-year survival rates of LS-SCLC patients in the control group and experimental group were 74.3%
31.4%
14.3%
11.4% and 77.1%
40.0%
28.6%
22.9% respectively
and the median survival for two groups were 16.1 months and 22.3 months respectively.The difference of survival rate at years 2
3
5 in two groups had statistically significance(P<0.05).But the difference of gastrointestinal reactions and myelosuppression atⅠ
Ⅱ levels during strengthen phase in two groups had no statistically significance(P>0.05).Conclusion:Chinese medcine treatment after conventional chemoradiotherapy can improve the survival rate and lengthen the survival time of LS-SCLC patients without increasing toxic side effects.
局限期小细胞肺癌放化疗后中药维持治疗中西医结合治疗
Limited stage small cell lung cancerPost-chemora-diotherapyFollow up treatment by Chinaes medicinecombination of Chinese and Western medicine treatment
0
浏览量
242
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621